Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

ClinicalTrials.gov ID: NCT00006291

Public ClinicalTrials.gov record NCT00006291. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Partially Blinded Trial of Combinations of Potent Antiretroviral Therapy, HIV-Specific Immunizations, and Cycles of Interleukin-2 to Promote Efficient Control of Viral Replication

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to see if adding an HIV vaccine (ALVAC-HIV vCP1452), IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system), or both to anti-HIV-drug therapy is safe, tolerable, and effective in controlling viral load (level of HIV in the body). (This study has been changed to clarify drug name.) Anti-HIV drugs can help reduce a patient's viral load. However, HIV can still remain in CD4 cells (cells of the immune system that help fight infection). Combining an HIV vaccine, IL-2, or both with anti-HIV drugs may help reduce the number of HIV-infected cells.

Study identification

NCT ID
NCT00006291
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
100 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Sep 30, 2005
Last update posted
Oct 31, 2021

Ends 2005

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Alabama Therapeutics CRS Birmingham Alabama 35294
USC CRS Los Angeles California 900331079
UCLA CARE Center CRS Los Angeles California 90095
Stanford CRS Palo Alto California 943055107
Ucsf Aids Crs San Francisco California 94110
Santa Clara Valley Med. Ctr. San Jose California 951282699
San Mateo County AIDS Program San Mateo California 943055107
Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic San Rafael California
Harbor-UCLA Med. Ctr. CRS Torrance California 90502
University of Colorado Hospital CRS Aurora Colorado 80262
Univ. of Miami AIDS CRS Miami Florida 331361013
The Ponce de Leon Ctr. CRS Atlanta Georgia
Univ. of Hawaii at Manoa, Leahi Hosp. Honolulu Hawaii 96816
Northwestern University CRS Chicago Illinois 60611
Indiana Univ. School of Medicine, Infectious Disease Research Clinic Indianapolis Indiana 462025250
Indiana Univ. School of Medicine, Wishard Memorial Indianapolis Indiana 46202
Methodist Hosp. of Indiana Indianapolis Indiana 46202
University of Minnesota, ACTU Minneapolis Minnesota 55455
Beth Israel Med. Ctr., ACTU New York New York 10003
NY Univ. HIV/AIDS CRS New York New York 10016
Univ. of Rochester ACTG CRS Rochester New York 14642
Unc Aids Crs Chapel Hill North Carolina 275997215
Hosp. of the Univ. of Pennsylvania CRS Philadelphia Pennsylvania 19104
Vanderbilt Therapeutics CRS Nashville Tennessee 37203
Univ. of Texas Medical Branch, ACTU Galveston Texas 775550435

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00006291, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 31, 2021 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00006291 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →